Shares of the pharmaceutical company Moderna during trading on Friday, on December 10, collapsed by 14.06 percent, from $ 272.21 to $ 233.95, after promuling the results of the efficiency of the seasonal influenza, the NASDAQ exchange data is evidenced. Later, the cost adjusted to $ 247.93.
The level of antibodies after flu vaccination with the MODERNA preparation turned out to be approximately one level with the French vaccine Sanofi Fluzone HD, Bloomberg reports. “The market was looking for a drug with greater efficiency,” wrote Morgan Stanley analyst Matthew Harrison.
Previously analysts predicted that flu vaccine can become a new source of income for Moderna, which specializes only on the release of drugs from coronavirus. In the case of successful tests, they expected rapid approval by regulatory authorities, however, due to weak results, the plans had to be postponed. The following intermediate research results will be published in the early 2022.
In early November, Moderna shares collapsed more than 20 percent after the news that the Pfizer competitor released a tablet from coronavirus with 89 percent efficiency. The paper of the company fell to 224 dollars.